Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.
Effects of the Anti-Inflammatory Antibody Canakinumab on Heart Disease and Cancer: Implications for HIV?
New study results prompt the question of whether canakinumab or other anti-inflammatories could have salutary clinical effects in HIV-positive people.
Many approaches being pursued as cancer therapeutics are also being studied in the context of HIV cure research, including immune checkpoint inhibitors, cytokine therapies, genetically modified chimeric antigen receptor (CAR) T cells and other gene t...
Women are drastically underrepresented in HIV cure research studies. The need for a cure is critical, but will the search for HIV cure strategies include women?
Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.
A report on three other cases of HIV-infected individuals receiving stem cell transplants indicates the likely role that CCR5 mutation plays in HIV remission or cure.
A review of HIV drugs in development that summarizes the most exciting new research over the previous year.
Scientists Hone in on the Best Way to Expose HIV Hidden in the Viral Reservoir, a Crucial Step Toward an Eventual Cure
Researchers at the University of North Carolina identified a better dosing strategy for a drug that exposes HIV hiding inside the body's viral reservoir, according to a new study.
Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.